65 related articles for article (PubMed ID: 10859696)
1. Synergistic approach to cancer therapy: exploiting interactions between anti-estrogens, retinoids, monoterpenes and tyrosine kinase inhibitors.
Lackey BR; Gray SL; Henricks DM
Med Hypotheses; 2000 May; 54(5):832-6. PubMed ID: 10859696
[TBL] [Abstract][Full Text] [Related]
2. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
3. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
de Jonge MJ; Verweij J
Eur J Cancer; 2006 Jul; 42(10):1351-6. PubMed ID: 16740386
[TBL] [Abstract][Full Text] [Related]
4. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
6. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
Morin MJ
Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
[TBL] [Abstract][Full Text] [Related]
7. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
Fry DW
Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032
[TBL] [Abstract][Full Text] [Related]
8. Retinoids as chemopreventive agents.
Ralhan R; Kaur J
J Biol Regul Homeost Agents; 2003; 17(1):66-91. PubMed ID: 12757022
[TBL] [Abstract][Full Text] [Related]
9. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates.
Ho SM
J Cell Biochem; 2004 Feb; 91(3):491-503. PubMed ID: 14755680
[TBL] [Abstract][Full Text] [Related]
10. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Engelman JA; Settleman J
Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
Sawyers CL
Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871
[No Abstract] [Full Text] [Related]
13. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR therapy update: clinical experience and adverse event insights.
Harari PM
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):3-4. PubMed ID: 16736977
[No Abstract] [Full Text] [Related]
15. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
Leirdal M; Sioud M
Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
[TBL] [Abstract][Full Text] [Related]
16. Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C.
Kim HJ; Kim TY
Br J Dermatol; 2005 Mar; 152(3):418-25. PubMed ID: 15787809
[TBL] [Abstract][Full Text] [Related]
17. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
18. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
19. Retinoids as preventive and therapeutic anticancer agents (Part II).
Lippman SM; Kessler JF; Meyskens FL
Cancer Treat Rep; 1987 May; 71(5):493-515. PubMed ID: 3552220
[No Abstract] [Full Text] [Related]
20. New targets for cancer therapy.
Coombes RC
Mol Aspects Med; 1993; 14(5):373-449. PubMed ID: 8208067
[No Abstract] [Full Text] [Related]
[Next] [New Search]
